Evidence map›Paper›PMID 36595094›Full record

ArticleNaunyn-Schmiedeberg's archives of pharmacology2023

Anti-cancer potential of substituted "amino-alkyl-rhodamine" derivatives against MCF-7 human breast cancer cell line.

Padma Charan Behera, Varnita Karmakar, Arya Ghosh, Suddhasatya Dey, Naresh Kumar Rangra, Bamaprasad Bag

Abstract read
PubMed Publisher
In one paragraph

Article in Naunyn-Schmiedeberg's archives of pharmacology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Padma Charan BeheraDepartment of Pharmaceutical Sciences, Jharkhand Rai University, Ratu Road, Ranchi, 835222, Jharkhand, India. padmabitmesra@gmail.com.
Varnita KarmakarDepartment of Pharmacology, Eminent College of Pharmaceutical Technology, Barasat, 700126, West Bengal, India.
Arya GhoshDepartment of Pharmaceutical Sciences, Jharkhand Rai University, Ratu Road, Ranchi, 835222, Jharkhand, India.
Suddhasatya DeyDepartment of Pharmacy, Sanaka Educational Trusts Group of Institutions, Durgapur, 713212, West Bengal, India.
Naresh Kumar RangraDepartment of Pharmaceutical Chemistry, ISF College of Pharmacy, Ghal-Kalan, GT Road, Moga, 142001, PB, India.
Bamaprasad BagMaterials Chemistry Department, CSIR-Institute of Minerals and Materials Technology, P.O.: R.R.L, Bhubaneswar, 751013, Odisha, India. bpbag@immt.res.in.

Funding

Science and Engineering Research Board EEQ/2020/000004
6 · The paper itself

Abstract

Breast cancer is the most prevalent diagnosed cancer among women and the main cause of morbidity and mortality. As for breast cancer, MCF-7 cells are an important candidate since they are widely utilized in research for estrogen receptor (ER)-positive breast cancer cell assays, and various sub-clones have been identified to reflect different classes of ER-positive tumors with varied levels of nuclear receptor expression. Rhodamines and its derivatives have shown a great interest over the past two decades due to their excellent structural and spectroscopic properties. Rhodamine derivatives have been widely investigated for their mitochondrial targeting and chemotherapeutic properties. Rhodamine derivatives, in particular, have been widely investigated for their therapeutic properties. In this regard, several studies have shown that rhodamine dye derivatives have promising in vitro and in vivo therapeutic efficacy. The present study deals with potential anticancer activity of few synthesized rhodamine derivatives against MCF-7 cell lines.

Indexed as

Antineoplastic AgentsBreast NeoplasmsRhodaminesCell Line, TumorCell ProliferationFemaleHumansMCF-7 CellsAntineoplastic AgentsRhodaminesAnti-proliferative activityIn vitro studiesMammalian breast cancerMCF-7 cell lineRhodamine derivatives

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.